While Allergan plans to diversify its portfolio in migraine by acquiring partner MAP and its candidate for acute migraine, NuPathe seeks a partner for a triptan patch product expected to avoid the nausea suffered by many migraine patients.

After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.